These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33947414)

  • 1. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Cottin V; Spagnolo P; Bonniaud P; Dalon F; Nolin M; Kirchgässler KU; Van Ganse E; Belhassen M
    Respir Med Res; 2023 Jun; 83():100951. PubMed ID: 36434913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.
    Lee CT; Hao W; Burg CA; Best J; Kolenic GE; Strek ME
    Respir Res; 2024 Jun; 25(1):255. PubMed ID: 38907239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
    Dempsey TM; Sangaralingham LR; Yao X; Sanghavi D; Shah ND; Limper AH
    Am J Respir Crit Care Med; 2019 Jul; 200(2):168-174. PubMed ID: 31150266
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
    Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
    Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Kou M; Jiao Y; Li Z; Wei B; Li Y; Cai Y; Wei W
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1445-1460. PubMed ID: 38963453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.
    Hozumi H; Miyashita K; Nakatani E; Inoue Y; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Respir Res; 2024 Jul; 25(1):293. PubMed ID: 39085869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; de Andrade J
    J Med Econ; 2022; 25(1):532-540. PubMed ID: 35321616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic evaluation in idiopathic pulmonary fibrosis in France.
    Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
    Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study.
    Romero Ortiz AD; Jiménez-Rodríguez BM; López-Ramírez C; López-Bauzá Á; Pérez-Morales M; Delgado-Torralbo JA; Villalba Moral C; Alcazar-Navarrete B
    BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38663886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.